S R Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
- Paid Up Capital ₹ 2.40 Cr
- Company Age 42 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
- Satisfied Charges ₹ 3.17 Cr
- Revenue Growth -3.40%
- Profit Growth 147.85%
- Ebitda 152.80%
- Net Worth 9.75%
- Total Assets 1.21%
About S R Drugs
S R Drugs Pvt Ltd (SRDPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 June 1982 and has a history of 42 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.40 Cr.
The company currently has active open charges totaling ₹3.00 M. The company has closed loans amounting to ₹3.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suraiya Tambe, Ruknuddin Tambe, and Altaf Tambe serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231MH1982PTC027442
- Company No.
027442
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 1982
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at S R Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruknuddin Tambe  | Managing Director | 15-Jun-1982 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suraiya Tambe | Director | 15-Jun-1982 | Current |
| Altaf Tambe | Director | 05-Oct-2015 | Current |
Financial Performance of S R Drugs.
S R Drugs Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.4% decrease. The company also saw a substantial improvement in profitability, with a 147.85% increase in profit. The company's net worth moved up by a moderate rise of 9.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S R Drugs?
In 2023, S R Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indian Oxalate LimitedSuraiya Tambe, Ruknuddin Tambe and 1 more are mutual person
Charges (Loans)
₹0.30 Cr
₹3.17 Cr
Charges Breakdown by Lending Institutions
- The State Ind. Investment Corp. Of Maharashtra Ltd. : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 1984 | The State Ind. Investment Corp. Of Maharashtra Ltd. | ₹3.00 M | Open |
| 06 Mar 1998 | Bank Of India | ₹2.00 Cr | Satisfied |
| 26 Aug 1997 | Bank Of India | ₹5.50 M | Satisfied |
| 26 Aug 1997 | Bank Of India | ₹5.50 M | Satisfied |
| 17 Aug 1985 | Bank Of India | ₹0.70 M | Satisfied |
How Many Employees Work at S R Drugs?
Unlock and access historical data on people associated with S R Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S R Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S R Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.